Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Published Online
on April 25, 2002

Arteriosclerosis, Thrombosis, and Vascular Biology. 2002
Published online before print April 25, 2002, doi: 10.1161/01.ATV.0000020007.25154.62
A more recent version of this article appeared on June 1, 2002
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
22/6/1042    most recent
01.ATV.0000020007.25154.62v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Acevedo, M.
Right arrow Articles by Sprecher, D. L.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Acevedo, M.
Right arrow Articles by Sprecher, D. L.
Related Collections
Right arrow Risk Factors
Right arrow Thrombosis risk factors
Right arrow Epidemiology

Submitted on February 18, 2002
Accepted on April 11, 2002

Elevated Fibrinogen and Homocysteine Levels Enhance the Risk of Mortality in Patients From a High-Risk Preventive Cardiology Clinic

Monica Acevedo ; Gregory L. Pearce ; Kandice Kottke-Marchant ; and Dennis L. Sprecher *

From the Departments of Cardiovascular Medicine (M.A., D.L.S., G.L.P., K.K.-M.), Section of Preventive Cardiology and Cardiac Rehabilitation (M.A., D.L.S., G.L.P.), and Clinical Pathology (K.K.-M.), The Cleveland Clinic Foundation, Cleveland, Ohio.

* To whom correspondence should be addressed. E-mail: sprechd{at}ccf.org.

Abstract—Fibrinogen (Fib) plays an important role in platelet aggregation and thrombus formation, and homocysteine (tHcy) causes endothelial dysfunction and injury. Therefore, an interaction toward an enhanced risk of thrombotic events and consequent mortality might be expected in patients with both factors elevated. To determine whether patients exposed jointly to high Fib and high tHcy were at increased risk of mortality, we compared them with those with only one or neither risk factors elevated. Prevalence of coronary artery disease (cross-section) and short-term mortality (30±14 months) were assessed in 2084 patients with available baseline tHcy and Fib. Upper quartiles were used to define high tHcy (>14.2 µmol/L) and high Fib (>382 mg/dL). Cox models adjusting for Framingham risk score, creatinine, and coronary artery disease status were used to estimate the risk of high tHcy and high Fib and their combinations. Mean age of the patients was 56±12 years (35% women) with 71 (3.4%) recorded deaths. Risk-adjusted longitudinal models showed a hazard ratio of 2.14 (P=0.03) for isolated high tHcy, 2.28 (P=0.02) for isolated high Fib, and 3.29 (P<0.001) for both high tHcy and high Fib in comparison with neither risk factor high. Independence of each parameter and lack of synergism was found on longitudinal as well as cross-sectional analyses. Conjoint elevation of Fib and tHcy increased the risk of death by approximately 3-fold in three years. Although no significant interaction between Fib and tHcy was demonstrated, both provided independent information after adjustment for traditional risk factors.


Key words: fibrinogen • homocysteine • mortality • risk